InvestorsHub Logo
Followers 839
Posts 120506
Boards Moderated 18
Alias Born 09/05/2002

Re: jbog post# 15020

Thursday, 11/19/2015 4:25:16 PM

Thursday, November 19, 2015 4:25:16 PM

Post# of 20689
If MYL succeeds at the USPTO in invalidating these patents, all companies seeking to market generic versions of 40mg Copaxone benefit.

However, no matter what happens with Teva's 40mg Copaxone patents, Teva has H-W exclusivity on 40mg Copaxone until 1/28/17 (http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=020622&Product_No=003&table1=OB_Rx ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”